{"id":"ulipristal-acetate-upa","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dysmenorrhea"},{"rate":"5-10%","effect":"Vaginal bleeding"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"As a SPRM, ulipristal acetate binds to the progesterone receptor, altering its function and preventing the typical effects of progesterone on the reproductive system. This results in a decrease in the likelihood of ovulation and an increase in the thickness of cervical mucus, making it more difficult for sperm to penetrate the cervix.","oneSentence":"Ulipristal acetate acts as a selective progesterone receptor modulator (SPRM) to prevent ovulation and thicken cervical mucus, thereby inhibiting sperm penetration.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:22.498Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Emergency contraception"},{"name":"Treatment of moderate to severe symptoms of uterine fibroids"}]},"trialDetails":[{"nctId":"NCT03537768","phase":"PHASE4","title":"Study Comparing Emergency Contraception Effectiveness in Women Who Weight ≥ 80 kg","status":"TERMINATED","sponsor":"Kimberly Myer","startDate":"2018-07-12","conditions":"Contraception","enrollment":532},{"nctId":"NCT03296098","phase":"PHASE2","title":"Study of the Safety and Efficacy of Ulipristal Acetate (UPA) Used Daily as a Contraceptive","status":"WITHDRAWN","sponsor":"Premier Research","startDate":"2020-12","conditions":"Contraception, Healthy Female","enrollment":""},{"nctId":"NCT06727734","phase":"PHASE3","title":"Levonorgestrel-piroxicam Versus Ulipristal Acetate for Emergency Contraception","status":"NOT_YET_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2024-12","conditions":"Contraception","enrollment":980},{"nctId":"NCT04291001","phase":"EARLY_PHASE1","title":"Ovarian Function With ENG Implant and UPA Use","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-09-04","conditions":"Contraception","enrollment":40},{"nctId":"NCT04004884","phase":"","title":"Liver Safety Assessment During Ulipristal Acetate Treatment for Uterine Fibroids (LISA)","status":"TERMINATED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2019-05-23","conditions":"Leiomyoma, Uterine, Liver Injury, Treatment Side Effects","enrollment":30},{"nctId":"NCT02859337","phase":"PHASE4","title":"Effectiveness of Orally Dosed Emergency Contraception in Obese Women - UPA","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2017-05-30","conditions":"Obesity, Contraception","enrollment":64},{"nctId":"NCT05216952","phase":"PHASE2","title":"Ulipristal Acetate for Use in Early Pregnancy Loss","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2022-05-11","conditions":"Missed Abortion, Anembryonic Pregnancy, Non-Viable Pregnancy","enrollment":3},{"nctId":"NCT04132349","phase":"PHASE4","title":"Ulipristal Acetate in Symptomatic Uterine Fibroid","status":"TERMINATED","sponsor":"Mỹ Đức Hospital","startDate":"2019-10-23","conditions":"Uterine Fibroid, Heavy Menstrual Bleeding","enrollment":25},{"nctId":"NCT02922127","phase":"PHASE1","title":"Compare Daily Ulipristal Acetate and Combined Oral Contraceptive Effects on Breast Epithelial Cell Proliferation","status":"COMPLETED","sponsor":"Columbia University","startDate":"2016-12-16","conditions":"Contraception","enrollment":29},{"nctId":"NCT03027973","phase":"PHASE1","title":"Quality of Life Outcomes for Ulipristal Acetate and Tranexamic Acid in the Management of Heavy Menstrual Bleeding","status":"WITHDRAWN","sponsor":"University of Saskatchewan","startDate":"2020-01","conditions":"Heavy Menstrual Bleeding","enrollment":""},{"nctId":"NCT02577601","phase":"PHASE4","title":"Impact of Combined Hormonal Contraceptives on UPA","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2015-09-08","conditions":"Contraception","enrollment":36},{"nctId":"NCT02147158","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Ulipristal Acetate Intermittent Treatment for Abnormal Uterine Bleeding Associated With Leiomyomas","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-01-29","conditions":"Leiomyoma, Uterine Hemorrhage","enrollment":432},{"nctId":"NCT02147197","phase":"PHASE3","title":"A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-03-31","conditions":"Leiomyoma, Uterine Hemorrhage","enrollment":157},{"nctId":"NCT03186586","phase":"PHASE4","title":"Ulipristal Versus Placebo for Women With Bleeding Induced by Mirena","status":"UNKNOWN","sponsor":"University of Campinas, Brazil","startDate":"2017-07-01","conditions":"Heavy Menstrual Bleeding, Abnormal Bleeding","enrollment":32},{"nctId":"NCT03230539","phase":"PHASE1","title":"A proof-of Concept, Randomized 3-month Study to Evaluate the Effects of Three Contraceptive Intrauterine Systems Delivering Copper and a Daily Dose of 5, 20 or 40 μg of Ulipristal Acetate (UPA)","status":"UNKNOWN","sponsor":"Population Council","startDate":"2017-05-01","conditions":"Contraception","enrollment":30},{"nctId":"NCT02689804","phase":"PHASE4","title":"EC PK in Women With Normal and Obese BMI","status":"COMPLETED","sponsor":"Columbia University","startDate":"2015-07-10","conditions":"Contraception","enrollment":34},{"nctId":"NCT02361892","phase":"PHASE4","title":"The Effect of Ulipristal Acetate (UPA) on Women Ovarian Reserve","status":"UNKNOWN","sponsor":"University Magna Graecia","startDate":"2015-02","conditions":"Infertility","enrollment":73},{"nctId":"NCT02601196","phase":"PHASE4","title":"IVF Outcome Following Treatment With Ulipristal Acetate for Myomatous Uterus After at Least One IVF Failure","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2016-09","conditions":"Women With Leiomyoma After at Least One Unsuccessful IVF Treatment","enrollment":20},{"nctId":"NCT01953679","phase":"PHASE2","title":"Efficacy Study of Two Continuous Regimens of Oral Daily 5 mg or 10 mg of Ulipristal Acetate (UPA), Versus a Dose of 5.0mg UPA for 24/4 Days","status":"COMPLETED","sponsor":"Premier Research","startDate":"2014-03","conditions":"Focus: Estrogen-free Oral Contraception","enrollment":180},{"nctId":"NCT01569113","phase":"PHASE4","title":"Assessment of Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOne® or Placebo.","status":"COMPLETED","sponsor":"HRA Pharma","startDate":"2012-03","conditions":"Emergency Contraception","enrollment":76},{"nctId":"NCT01553123","phase":"PHASE3","title":"Efficacy and Safety Study of Ulipristal Acetate in Females With Anemia Associated With Uterine Leiomyoma","status":"WITHDRAWN","sponsor":"Watson Pharmaceuticals","startDate":"2012-04","conditions":"Leiomyomas","enrollment":""},{"nctId":"NCT01391845","phase":"NA","title":"Ulipristal Acetate on Progesterone Levels and Glycodelin-A Endometrial Pattern","status":"UNKNOWN","sponsor":"Programa de Asistencia Reproductiva de Rosario","startDate":"2011-07","conditions":"Infertility","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ulipristal acetate (UPA)","genericName":"Ulipristal acetate (UPA)","companyName":"Allergan","companyId":"allergan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ulipristal acetate acts as a selective progesterone receptor modulator (SPRM) to prevent ovulation and thicken cervical mucus, thereby inhibiting sperm penetration. Used for Emergency contraception, Treatment of moderate to severe symptoms of uterine fibroids.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}